Johnson, Kristin http://orcid.org/0000-0002-5099-423X
Olinder, Jakob
Rosso, Aldana
Andersson, Ingvar
Lång, Kristina
Zackrisson, Sophia
Funding for this research was provided by:
Cancerfonden
Vetenskapsrådet
Svenska Sällskapet för Medicinsk Forskning
Gunnar Nilssons Cancerstiftelse
Skånes universitetssjukhus
Allmänna Sjukhusets i Malmö Stiftelse för Bekämpande av Cancer
Lund University
Article History
Received: 13 October 2022
Revised: 20 March 2023
Accepted: 25 March 2023
First Online: 5 May 2023
Declarations
:
: The scientific guarantor of this publication is Sophia Zackrisson.
: The authors of this manuscript declare relationships with the following companies: Siemens Healthineers, Pfizer, and BayerAG. SZ is a patent owner (US patent no PCT/EP2014/057372).
: One of the authors (AR) has significant statistical expertise.
: Written informed consent was obtained from all subjects in this study.
: Institutional review board approval was obtained.
: Some study objects have been previously reported (1–3).1. Lang K, Nergarden M, Andersson I, Rosso A, Zackrisson S. False positives in breast cancer screening with one-view breast tomosynthesis: an analysis of findings leading to recall, work-up and biopsy rates in the Malmo Breast Tomosynthesis Screening Trial. Eur Radiol. 2016;26(11):3899–907.2. Rosso A, Lang K, Petersson IF, Zackrisson S. Factors affecting recall rate and false positive fraction in breast cancer screening with breast tomosynthesis—a statistical approach. Breast. 2015;24(5):680–6.3. Zackrisson S, Lang K, Rosso A, Johnson K, Dustler M, Fornvik D, et al One-view breast tomosynthesis versus two-view mammography in the Malmo Breast Tomosynthesis Screening Trial (MBTST): a prospective, population-based, diagnostic accuracy study. Lancet Oncol. 2018;19(11):1493–503.
: • Prospective• Diagnostic study• Performed at one institution